Advertisement

Targeted Oncology

, Volume 14, Issue 2, pp 237–246 | Cite as

Rucaparib: A Review in Ovarian Cancer

  • Matt ShirleyEmail author
Adis Drug Evaluation

Abstract

Rucaparib (Rubraca®) is a small molecule poly(ADP-ribose) polymerase (PARP) inhibitor with potent activity against PARP-1, -2 and -3. It is approved in the USA and the EU for the treatment of adult patients with BRCA-mutated ovarian cancer who have been treated with two or more lines of chemotherapy. Rucaparib is also approved in the USA and the EU for use as maintenance therapy in adult patients with recurrent or relapsed ovarian cancer who are in a complete or partial response to platinum-based chemotherapy. Based on an analysis of patients across two phase II clinical trials, rucaparib displayed clinical activity as third- (or later-) line treatment of BRCA-mutated ovarian cancer, with rucaparib-treated patients having a confirmed objective response rate of 54%. Furthermore, as demonstrated in the randomized, placebo-controlled, phase III ARIEL3 trial, rucaparib significantly improved progression-free survival when used as maintenance treatment in patients with platinum-sensitive ovarian cancer. Rucaparib had an acceptable tolerability profile in clinical trials in women with ovarian cancer. Common adverse events were generally manageable with dose modification and/or supportive care. Thus, currently available data indicate that rucaparib is a useful addition to the options available to clinicians for the treatment of advanced ovarian cancer, in both the treatment and maintenance therapy settings.

Notes

Acknowledgements

During the peer review process, the manufacturer of rucaparib was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Matt Shirley is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    International Agency for Research on Cancer. Cancer Today; 2019. http://gco.iarc.fr/today/home. Accessed 22 Jan 2019.
  2. 2.
    Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi24–32.CrossRefGoogle Scholar
  3. 3.
    Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9–32.CrossRefGoogle Scholar
  4. 4.
    The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15.CrossRefGoogle Scholar
  5. 5.
    National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology (NCCN Guidelines®): ovarian cancer including fallopian tube cancer and primary peritoneal cancer (version 2.2018); 2018. http://www.nccn.org. Accessed 07 Feb 2019.
  6. 6.
    Schreiber V, Dantzer F, Amé J-C, et al. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol. 2006;7(7):517–28.CrossRefGoogle Scholar
  7. 7.
    Boehler C, Gauthier LR, Mortusewicz O, et al. Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression. Proc Natl Acad Sci USA. 2011;108(7):2783–8.CrossRefGoogle Scholar
  8. 8.
    Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–7.CrossRefGoogle Scholar
  9. 9.
    Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21.CrossRefGoogle Scholar
  10. 10.
    Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005;5(9):689–98.CrossRefGoogle Scholar
  11. 11.
    McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66(16):8109–15.CrossRefGoogle Scholar
  12. 12.
    US FDA. Rubraca® (rucaparib) tablets: US prescribing information. 2018. http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf. Accessed 26 Feb 2019.
  13. 13.
    European Commission. Rubraca: summary of product characteristics. 2019. http://www.ema.europa.eu/documents/product-information/rubraca-epar-product-information_en.pdf. Accessed 26 Feb 2019.
  14. 14.
    Robillard L, Nguyen M, Harding TC, et al. In vitro and in vivo assessment of the mechanism of action of the PARP inhibitor rucaparib [abstract no. 2475]. Cancer Res. 2017;77(13 Suppl):2475.CrossRefGoogle Scholar
  15. 15.
    Drew Y, Ledermann J, Hall G, et al. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer. 2016;114(7):723–30.CrossRefGoogle Scholar
  16. 16.
    Murai J, Huang S-YN, Renaud A, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2014;13(2):433–43.CrossRefGoogle Scholar
  17. 17.
    Drew Y, Mulligan EA, Vong W-T, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst. 2011;103(4):334–46.CrossRefGoogle Scholar
  18. 18.
    Ihnen M, zu Eulenburg C, Kolarova T, et al. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. Mol Cancer Ther. 2013;12(6):1002–15.CrossRefGoogle Scholar
  19. 19.
    Murray J, Thomas H, Berry P, et al. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. Br J Cancer. 2014;110(8):1977–84.CrossRefGoogle Scholar
  20. 20.
    Kristeleit R, Shapiro GI, Burris HA, et al. A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors. Clin Cancer Res. 2017;23(15):4095–106.CrossRefGoogle Scholar
  21. 21.
    Swisher EM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75–87.CrossRefGoogle Scholar
  22. 22.
    Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949–61.CrossRefGoogle Scholar
  23. 23.
    Shroff RT, Hendifar A, McWilliams RR, et al. Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation. JCO Precis Oncol. 2018.  https://doi.org/10.1200/po.17.00316.Google Scholar
  24. 24.
    Falzacappa MVV, Ronchini C, Faretta M, et al. The combination of the PARP inhibitor rucaparib and 5FU is an effective strategy for treating acute leukemias. Mol Cancer Ther. 2015;14(4):889–98.CrossRefGoogle Scholar
  25. 25.
    Daniel RA, Rozanska AL, Mulligan EA, et al. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. Br J Cancer. 2010;103(10):1588–96.CrossRefGoogle Scholar
  26. 26.
    Nile DL, Rae C, Hyndman IJ, et al. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma. BMC Cancer. 2016;16:621.CrossRefGoogle Scholar
  27. 27.
    Bouwman P, Jonkers J. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? Clin Cancer Res. 2014;20(3):540–7.CrossRefGoogle Scholar
  28. 28.
    Kondrashova O, Nguyen M, Shield-Artin K, et al. Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2017;7(9):984–98.CrossRefGoogle Scholar
  29. 29.
    Wang Y-T, Yuan B, Chen H-D, et al. Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression. Cancer Sci. 2018;109(3):821–31.CrossRefGoogle Scholar
  30. 30.
    McCormick A, Donoghue P, Dixon M, et al. Ovarian cancers harbor defects in nonhomologous end joining resulting in resistance to rucaparib. Clin Cancer Res. 2017;23(8):2050–60.CrossRefGoogle Scholar
  31. 31.
    Durmus S, Sparidans RW, van Esch A, et al. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699). Pharm Res. 2015;32(1):37–46.CrossRefGoogle Scholar
  32. 32.
    Shapiro GI, Kristeleit RS, Burris HA, et al. Pharmacokinetic study of rucaparib in patients with advanced solid tumors. Clin Pharmacol Drug Dev. 2018;8(1):107–18.CrossRefGoogle Scholar
  33. 33.
    Wilson RH, Evans TRJ, Middleton MR, et al. A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. Br J Cancer. 2017;116(7):884–92.CrossRefGoogle Scholar
  34. 34.
    Xiao JJ, Green M, Ma S, et al. Population pharmacokinetics (PK) of rucaparib (CO-338) in patients with advanced ovarian cancer (AOC) or other solid tumors [abstract no. PII-144]. Clin Pharmacol Ther. 2017;101(Suppl. 1):S92.Google Scholar
  35. 35.
    Xiao JJ, Nowak D, Ramlau R, et al. Evaluation of drug-drug interactions of rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp substrates in patients with an advanced solid tumor. Clin Transl Sci. 2019;12(1):58–65.CrossRefGoogle Scholar
  36. 36.
    Oza AM, Tinker AV, Oaknin A, et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol. 2017;147(2):267–75.CrossRefGoogle Scholar
  37. 37.
    Keating GM. Bevacizumab: a review of its use in advanced cancer. Drugs. 2014;74(16):1891–925.CrossRefGoogle Scholar
  38. 38.
    Heo Y-A, Duggan ST. Niraparib: a review in ovarian cancer. Target Oncol. 2018;13(4):533–9.CrossRefGoogle Scholar
  39. 39.
    Frampton JE. Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer. BioDrugs. 2015;29(2):143–50.CrossRefGoogle Scholar
  40. 40.
    Ledermann J, Sessa C, Colombo N. eUpdate—ovarian cancer treatment recommendations; 2016. http://www.esmo.org/Guidelines/Gynaecological-Cancers/Newly-Diagnosed-and-Relapsed-Epithelial-Ovarian-Carcinoma/eUpdate-Treatment-Recommendations. Accessed 07 Feb 2019.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations